Clinical Trials Logo

Arachnophobia clinical trials

View clinical trials related to Arachnophobia.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05424250 Completed - Arachnophobia Clinical Trials

Optimizing Exposure Using Occasional Aversive Imagery in Spider Fearful Individuals

Start date: June 15, 2022
Phase: N/A
Study type: Interventional

The effectiveness of an optimized extinction training is investigated in spider-fearful individuals. Participants will undergo a one-session standardized extinction training, either with or without occasional metal imagination of most feared apprehension towards spiders. The effectiveness of the training is measured by symptom improvement according to subjective ratings and behavioural avoidance tests one week later.

NCT ID: NCT04663672 Completed - Clinical trials for Obsessive-Compulsive Disorder

Efficacy of Targeted Memory Reactivation for Enhancing Exposure Therapy

Start date: January 29, 2019
Phase: N/A
Study type: Interventional

This study evaluates whether a scent applied during exposure therapy and during subsequent sleep will increase the durability of treatment effects for individuals with fear of spiders, contamination, and enclosed spaces.

NCT ID: NCT04470882 Completed - Specific Phobia Clinical Trials

Use of Safety Behaviors in Exposure Therapy for Arachnophobia

Start date: February 28, 2019
Phase: N/A
Study type: Interventional

This study examines the impact of safety behaviors (i.e., unnecessary protective actions) on outcomes of exposure therapy for spider phobia. Researchers will compare exposure therapy with (a) no safety behaviors, (b) safety behaviors faded toward the end of treatment, and (c) unfaded safety behaviors.

NCT ID: NCT03934385 Completed - Anxiety Disorders Clinical Trials

Optimizing Exposure Therapy With Mental Rehearsal

Start date: October 23, 2018
Phase: N/A
Study type: Interventional

Treatment response rates for cognitive behavioral therapy (CBT) across anxiety disorders average approximately 50% post-treatment (Loerinc et al, 2015), evidencing significant 'return of fear', the re-emergence of a partially or fully extinguished fear (Rachman, 1989). Thus, recent research has amplified efforts toward improving treatment methodology in an attempt to optimize clinical outcomes. Many efforts have targeted exposure therapy, an evidence-based behavioral technique during which a patient is strategically and repeatedly exposed to his or her feared stimulus in an effort to generate new non-fear associations with that stimulus. One such effort involves mental rehearsal, where information is reinstated using either a cue from extinction training or imaginal recounting of previous successful exposures (Craske et al, 2014). Prior research has assessed the effects of mental rehearsal via reinstatement of the extinction context (i.e., treatment context) or of cues/items from the treatment context that may indicate safety (e.g., Mystkowski et al, 2006; Culver, Stoyanova, & Craske, 2011). However, this research has produced inconsistent results and contains an inherent limitation, as retrieval cues may become a safety signal and inhibit new learning (Dibbets, Havermans, & Arntz, 2008). In an effort to address these limitations, the current study recruits spider-fearful participants for a treatment trial consisting of exposures in conjunction with either a mental rehearsal intervention, or a control rehearsal intervention. The overarching goal of this project is to evaluate the extent to which a between-session, technology-guided mental rehearsal intervention may optimize exposure therapy outcomes. We also seek to evaluate potential mechanisms of mental rehearsal. Participants complete three laboratory visits, including two sessions of exposures with live spiders. Participants are randomized to either a mental rehearsal or control rehearsal condition to measure potential mechanisms and moderators of mental rehearsal. Laboratory-based assessments include measures of subjective, behavioral, and psychophysiological responses to spiders.